Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas

British Journal of Cancer

Volumn 93, Issue 11, 2005, Pages 1250-1256

  Berta, G N ^a   Mognetti, B ^a   Spadaro, M ^a   Trione, E ^a   Amici, A ^b   Forni, G ^a   Di Carlo, F ^a   Cavallo, F ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Cancer vaccine; DNA vaccination; HER 2; Immunoprevention; Oral squamous cell carcinoma

Indexed keywords

DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; ELECTRODE; ELECTROPORATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SQUAMOUS CELL CARCINOMA; VACCINATION;

ANIMALS; ANTIBODY FORMATION; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CRICETINAE; ELECTROPORATION; MALE; MESOCRICETUS; MOUTH NEOPLASMS; RECEPTOR, ERBB-2; TRANSPLANTATION, HETEROLOGOUS; VACCINES, DNA;

EID: 27944460462     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602853     Document Type: Article

References (46)

1. Billingham RE, Hildemann WH (1958) Studies of transplantation immunity in hamsters. Ann N Y Acad Sci 73: 676-686
2. Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, Lewis JJ, Houghton AN (1999) Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 190: 1717-1722
3. Cappello P, Triebel F, Iezzi M, Caorsi C, Quaglino E, Lollini PL, Amici A, Di Carlo E, Musiani P, Giovarelli M, Forni G (2003) LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res 63: 2518-2525
4. Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A, Forni G (1992) Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-12 gene transfection. J Immunol 149: 3627-3635
5. Chen IH, Chang JT, Liao CT, Wang HM, Hsieh LL, Cheng AJ (2003) Significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis. Br J Cancer 89: 681-686
6. Cortesina G, De Stefani A, Galeazzi E, Cavallo GP, Badellino F, Margarino G, Jemma C, Forni G (1994) Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br J Cancer 69: 572-576
7. Dako HercepTest™ (2000) A Manual for Interpretation, pp 7-8
8. Day GL, Blot WJ (1992) Second primary tumors in patients with oral cancer. Cancer 70: 14-19
9. de Cassia Braga Ribeiro K, Kowalski LP, Latorre Mdo R (2003) Perioperative complications, comorbidities, and survival in oral or oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 129: 219-228
10. Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL, Penichet ML (2003) Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine 21: 1317-1326
11. De Stefani A, Forni G, Ragona R, Cavallo G, Bussi M, Usai A, Badellino F, Cortesina G (2002) Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer 95: 90-97
12. Di Carlo E, Rovero S, Boggio K, Quaglino E, Amici A, Smorlesi A, Forni G, Musiani P (2001) Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. Clin Cancer Res 7: 830-837s
13. Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, Piskun G, Lewis JJ, Houghton AN, Nikolic-Zugic J (1998) Heteroclitic immunization induces tumor immunity. J Exp Med 188: 1553-1561
14. Gehl J (2003) Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 177: 437-447
15. Gilboa E (2004) The promise of cancer vaccines. Nat Rev Cancer 4: 401-411
16. Handler AH, Davis S, Sommers SC (1956) Heterotransplantation experiments with human cancers. Cancer Res 16: 32-36
17. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52-58
18. Ignatoski KM, Lapointe AJ, Radany EH, Ethier SP (1999) erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology 140: 3615-3622
19. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6: 332-336
20. Lowrie DB (2003) DNA vaccination: an update. Methods Mol Med 87: 377-390
21. Lutz BR, Patt DI (1952) I. White thromboembolism in the hamster cheek pouch after trauma, infection, and neoplasia; II. The use of the hamster cheek pouch as a site for homologous and heterologous tumor transplantation. Bull N Engl Med Cent 14: 58-60
22. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK (1999) A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5: 1331-1338
23. Mort Telfer MR, Shepherd JP (1993) Psychological distress in patients attending an oncology clinic after definitive treatment for maxillofacial malignant neoplasia. Int J Oral Maxillofac Surg 22: 347-349
24. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL (1999) Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38: 73-78
25. Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, Astolfi A, Iezzi M, Di Carlo E, Musiani P, Forni G, Lollini PL (2004) Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol 173: 2288-2296
26. Nanni P, Pupa SM, Nicoletti G, De Giovanni C, Landuzzi L, Rossi I, Astolfi A, Ricci C, De Vecchi R, Invernizzi AM, Di Carlo E, Musiani P, Forni G, Menard S, Lollini PL (2000) p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 87: 186-194
27. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332
28. Odukoya O, Schwartz J, Weichselbaum R, Shklar G (1983) An epidermoid carcinoma cell line derived from hamster 7,12-dimethylben-z[a]anthracene-induced buccal pouch tumors. J Natl Cancer Inst 71: 1253-1264
29. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787
30. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP (1999) Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA 96: 2982-2987
31. Palm J, Silvers WK, Billingham RE (1967) The problem of histocompatibility in wild hamsters. J Hered 58: 40-44
32. Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC, Berzofsky JA (2005) Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus-vaccine protection against autochthonous mammary carcinomas. J Immunol 174: 4228-4236
33. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156
34. Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F (2004a) Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 64: 2858-2864
35. Quaglino E, Rolla S, Iezzi M, Spadaro M, Musiani P, De Giovanni C, Lollini PL, Lanzardo S, Forni G, Sanges R, Crispi S, De Luca P, Calogero R, Cavallo F (2004b) Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest 113: 709-717
36. Resnick B, Farber EM, Fulton GP (1960) Survival of human skin transplanted into the cheek pouch of the golden hamster. Arch Dermatol 81: 394-399
37. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide EC-TM for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327
38. Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, Giovarelli M, Musiani P, Forni G (2000) DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165: 5133-5142
39. Salley JJ (1954) Experimental carcinogenesis in the cheek pouch of the Syrian hamster. J Dent Res 33: 253-262
40. Shklar G, Eisenberg E, Flynn E (1979) Immunoenhancing agents and experimental leukoplakia and carcinoma of the hamster buccal pouch. Prog Exp Tumor Res 24: 269-282
41. Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C, Amici A, Wei WZ, Musiani P, Lollini PL, Cavallo F, Forni G (2005) Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neo-adjuvant IL12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res 11: 1941-1952
42. Trojan A, Witzens M, Schultze JL, Vonderheide RH, Harig S, Krackhardt AM, Stahel RA, Gribben JG (2001) Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res 61: 4761-4765
43. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) (1998) Guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 77: 1-10
44. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK (1993) Head and neck cancer. N Engl J Med 328: 184-194
45. Wollenberg B, Kastenbauer S, Mundl H, Schaumberg J, Mayer A, Andratschke M, Lang S, Pauli C, Zeidler R, Ihrler S, Lohrs U, Naujoks K, Rollston R (1999) Gene therapy - phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II -IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol. Hum Gene Ther 10: 141-147
46. Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, Li L, Katz RL, Hung MC (1999) Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5: 4164-4174